| 國立成功大學 |
2012-05 |
Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC)
|
Cheng, AL (Cheng, Ann-Lii); Kang, YK (Kang, Yoon-Koo); Ryoo, BY (Ryoo, Baek-Yeol); Yen, CJ (Yen, Chia-Jui); Lim, HY (Lim, Ho Yeong); Oh, DY (Oh, Do-Youn); Austin, T (Austin, TaShara); Wang, Q (Wang, Qiang); Greenberg, J (Greenberg, Jonathan); Beckman, RA (Beckman, Robert A.); Kudo, M (Kudo, Masatoshi) |
